Global Hyperimmune Globulins Market growing at a CAGR of 6.8% from 2023 to 2031
Category : Healthcare | Published Date : Dec 2023 | Type : Press Release
Key Market Overview
Consegic Business Intelligence analyzes that the hyperimmune globulins market is predicted to grow at a compound annual growth rate of 6.8% from 2023 to 2031 and is expected to reach USD 3,166.71 million in 2031 and 1,877.26 million in 2023 which was valued at USD 1,767.02 million in 2022.
The report highlights the rising incidences of infectious bacterial, viral, and chronic diseases and the growing adoption of immunoglobulin therapies, which is augmenting global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the Hyperimmune Globulins market.
Global Hyperimmune Globulins Market By Overview
The hyperimmune globulins market is bifurcated into product type, dosage form, and application. Based on the product type, the market is segmented into immunoglobulins for hepatitis B, immunoglobulins for botulism, immunoglobulins for rabies, immunoglobulins for tetanus, Rho (D) immunoglobulins, and others. In 2022, the Rho (D) immunoglobulins segment dominates the overall hyperimmune globulins market. Based on the dosage form, the market is segmented into liquid and powder forms. In 2022, the liquid form segment dominate the overall hyperimmune globulins market. Based on application, the market is segmented into infections, immunodeficiency, and autoimmune disorders. In 2022, the infection segment dominate the overall hyperimmune globulins market.
Get Free SampleMarket Dynamics
Driver:
- Rising incidences of infectious bacterial, viral, and chronic diseases.
- Growing adoption of immunoglobulin therapies.
Restraints:
- High cost of hyperimmune globulin product development leading to price sensitivity.
Market Segmentation:
| Report Attributes | Report Details |
| By Product Type | Immunoglobulins for Hepatitis B, Immunoglobulins for Botulism, Immunoglobulins for Rabies, Immunoglobulins for Tetanus, Rho (D) Immunoglobulins, and Others |
| By Dosage Form | Liquid Form and Powder Form |
| By Application | Infections, Immunodeficiency, and Autoimmune disorders |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Grifols, S.A., EMERGENT, Kamada Pharmaceuticals, and ADMA Biologics, Inc., which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the hyperimmune globulins market is expected to witness substantial growth in the coming years due to an increase in research and development activities across the healthcare and pharmaceutical sectors in key regions such as North America, Asia Pacific, and others.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- Grifols, S.A.
- ADMA Biologics, Inc.
- Octapharma AG
- Kedrion
- Shanghai RAAS Blood Products Co., Ltd.
- EMERGENT
- Biotest AG.
- CSL
- Kamada Pharmaceuticals.
- GigaGen
- Saol Therapeutics
